Veru Reports FY2025 Financial Results & Clinical Progress
Veru has secured FDA feedback that clarifies a regulatory path for enobosarm as an adjunct to GLP-1 receptor agonists...
Oncotelic Unveils Revolutionary DeciParticle™ Nanomedicine
Sapu Nano, a 45% owned joint venture of Oncotelic Therapeutics, reported new data at the 2025 San Antonio Breast...
Successful First Cohort for Onco3R’s New SIK3 Inhibitor
Onco3R Therapeutics has completed the first multiple-ascending-dose cohort in a Phase 1 study of its oral SIK3 inhibitor, O3R-5671,...
Promising Zorevunersen Data Offers Dravet Syndrome Hope
Biogen and Stoke Therapeutics unveiled new clinical and biomarker data for zorevunersen, an investigational antisense oligonucleotide for Dravet syndrome,...
XOMA Royalty Finalizes Acquisition of Mural Oncology plc
XOMA Royalty Corporation has completed its acquisition of Mural Oncology plc via an Irish High Court–sanctioned scheme of arrangement,...
Rezolute Phase 3 SUNRIZE Study Results for Hyperinsulinism
Rezolute reported topline data from its Phase 3 sunRIZE study in congenital hyperinsulinism showing that ersodetug did not meet...
Novartis: Pioneering Hematology & Oncology Data at ASH/SABCS
Novartis will flood the 2025 ASH and SABCS meetings with more than 70 data readouts, including 11 oral presentations...
Mesoblast’s Latest AGM Reveals Strong Ryoncil® Revenue Growth
Mesoblast expects more than $30 million in gross revenue from Ryoncil (remestemcel‑l‑rknd) sales for the quarter ending December 31,...
Pacira Sues WhiteOak, Qilu for Exparel Patent Infringement
Pacira BioSciences has filed patent infringement suits in the U.S. District Court for Delaware against The WhiteOak Group and...
Hutchmed Reveals New Clinical Data at ESMO & ASH Meetings
HUTCHMED will deliver a coordinated slate of oncology and hematology readouts across ESMO Asia and ASH in early December,...